Blood Stream Infection Testing Market Expected to Reach $10.54 Billion by 2030—Allied Market Research

According to a new report published by Allied Market Research, titled, “Blood Stream Infection Testing Market," The bloodstream infection testing market size was $5.17 billion in 2021, and is estimated to reach $10.54 billion by 2030, growing at a CAGR of 8.3% from 2022 to 2030.

Blood stream infection is a condition where any bacterial, fungal or any type of infection is detected in the blood. The condition is evident when the infection enters into the blood stream of any part of the body. The bacteria or organisms that causes the blood infection are determined by using blood stream infection testing. Increasing incidences of bloodstream infection in elderly population who are susceptible to infection due to low immunity is anticipated to drive the global bloodstream infection testing market demand and boost revenue growth of the market. The initiatives of various organizations to spread awareness regarding transfusion-transmitted infections is also expected to boost the market growth. High demand for technologically advanced diagnostic tests, awareness about hygiene, diagnosis rate, and unhealthy lifestyle are also expected to fuel the market growth over the forecast period.

However, absence of proper healthcare facilities related to medical testing, high diagnosis cost, and stringent regulatory situation acts as a hindrance to revenue growth of the market. The introduction of new cost-efficient and easy to use devices are projected to generate new opportunities for the major players within the forecast period.

According to the recent data by United Nations, as of July 2022, the global population has reached 7.96 billion. This rising population is predicted to fuel revenue growth of the blood stream infection testing market. According to the Centers for Disease Control and Prevention (CDC), patients with infections in the urinary tract, kidney, lung, and abdominal area are prone to suffer from Blood Stream Infection. In addition, people who are suffering with HIV or receiving chemotherapy treatment are at a higher risk of developing BSI. It is one of the serious complications for patients who are admitted in critical care units. This infection not only lengthens the hospital stay, but also increases chances of life-threatening comorbidities and sometimes leads to death.

The global bloodstream infection testing market is segmented based on product, technique, technology, application, end-user, and region. By product, the market is sub-segmented into instruments, consumables, and software & services. By technique, the market is sub-segmented into conventional and automated. By technology, the market is sub-segmented into culture-based, molecular, and proteomic. By application, the market is sub-segmented into bacterial, fungal, and mycobacterial. By end-user, the market is sub-segmented into hospitals, independent diagnostics centers, and others. By region, the market is sub-segmented into North America, Europe, Asia-Pacific, and LAMEA.

The major players in the global bloodstream infection testing market are Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Abbott, BD, BIOMÉRIEUX, Cepheid, Luminex Corporation, Accelerate Diagnostics Inc., AdvanDX, and Bruker.

The report offers a comprehensive analysis of the global bloodstream infection testing market trends by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards growth of the market. The report also sheds light on the present scenario and upcoming trends & developments that are contributing to the bloodstream infection testing market growth. Moreover, restraints and challenges that hold power to obstruct the bloodstream testing industry growth are also profiled in the report along with the Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market. These frameworks provide the complete Bloodstream Infection Testing Market Share.

Impact of Covid-19 on the Global Blood Stream Infection Testing Industry

• Businesses and economic activity around the world have been severely affected by the COVID-19 pandemic. Due to the low or non-existence of medical facilities/treatment centers, COVID-19 had a negative effect on the global bloodstream infection testing market
• Governments of various countries across the world were delaying or postponing unnecessary medical and surgical operations to relieve pressure on the healthcare system and minimize the spread of disease
• However, several market players developed a serology test/COVID-19 antibody test that uses a blood sample from the suspected individual. This started to increase the blood tests and also to cope the void created during the pandemic.

Key Findings of the Study

• Based on product, the consumables sub-segment is predicted hold the maximum market share and also to be the fastest growing sub-segment
• Based on technique, the conventional sub-segment is predicted to hold the maximum market share and the automated sub-segment is expected to grow with the highest CAGR over the forecast period 
• Based on technology, the culture-based sub-segment is predicted to have a high market share throughout the analysis period and the molecular sub-segment is predicted to grow at the highest CAGR in the estimated timeframe